Brivaracetam (CHEM099483)
| Record Information | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Version | 1.0 | |||||||||
| Creation Date | 2026-04-05 10:45:41 UTC | |||||||||
| Update Date | 2026-08-18 12:59:52 UTC | |||||||||
| Accession Number | CHEM099483 | |||||||||
| Identification | ||||||||||
| Common Name | Brivaracetam | |||||||||
| Class | Small Molecule | |||||||||
| Description | Brivaracetam is an organic compound with the formula C11H20N2O2 and an average molecular weight of 212.29 g/mol. Brivaracetam belongs to the amino acids, peptides, and analogues, a subclass of carboxylic acids and derivatives within the organic compounds. The compound is found in or released from one recorded source: healthcare, pharmaceuticals & veterinary products, where it is used as an antiepileptic. Recorded exposure routes for this substance include oral and intravenous administration. Brivaracetam interacts with 15 recorded protein targets, acting as an inhibitor or having an unknown effect on synaptic vesicle glycoprotein 2A (SV2A), sodium channel protein type 1 subunit alpha (SCN1A), sodium channel protein type 4 subunit alpha (SCN4A), sodium channel regulatory subunit beta-2 (SCN2B), and 11 other proteins. | |||||||||
| Contaminant Sources | Not Available | |||||||||
| Contaminant Type | Not Available | |||||||||
| Chemical Structure |  | |||||||||
| Synonyms | Not Available | |||||||||
| Chemical Formula | C11H20N2O2 | |||||||||
| Average Molecular Mass | 212.293 g/mol | |||||||||
| Monoisotopic Mass | 212.152 g/mol | |||||||||
| CAS Registry Number | 357336-20-0 | |||||||||
| IUPAC Name | (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide | |||||||||
| Traditional Name | Not Available | |||||||||
| SMILES | CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1 | |||||||||
| InChI Identifier | InChI=1S/C11H20N2O2/c1-3-5-8-6-10(14)13(7-8)9(4-2)11(12)15/h8-9H,3-7H2,1-2H3,(H2,12,15)/t8-,9+/m1/s1 | |||||||||
| InChI Key | MSYKRHVOOPPJKU-BDAKNGLRSA-N | |||||||||
| Chemical Taxonomy | ||||||||||
| Classification | Not classified | |||||||||
| Biological Properties | ||||||||||
| Status | Detected and Not Quantified | |||||||||
| Origin | Not Available | |||||||||
| Cellular Locations | Not Available | |||||||||
| Biofluid Locations | Not Available | |||||||||
| Tissue Locations | Not Available | |||||||||
| Pathways |
| |||||||||
| Applications | Not Available | |||||||||
| Biological Roles | Not Available | |||||||||
| Chemical Roles | Not Available | |||||||||
| Physical Properties | ||||||||||
| State | Not Available | |||||||||
| Appearance | Not Available | |||||||||
| Experimental Properties |
| |||||||||
| Predicted Properties | Not Available | |||||||||
| Spectra | ||||||||||
| Spectra |
| |||||||||
| Toxicity Profile | ||||||||||
| Route of Exposure | Not Available | |||||||||
| Mechanism of Toxicity | Not Available | |||||||||
| Metabolism | Not Available | |||||||||
| Toxicity Values | Not Available | |||||||||
| Lethal Dose | Not Available | |||||||||
| Carcinogenicity (IARC Classification) | Not Available | |||||||||
| Uses/Sources | Not Available | |||||||||
| Minimum Risk Level | Not Available | |||||||||
| Health Effects | Not Available | |||||||||
| Symptoms | Not Available | |||||||||
| Treatment | Not Available | |||||||||
| Concentrations | ||||||||||
| Not Available | ||||||||||
| External Links | ||||||||||
| Identifiers | Not Available | |||||||||
| References | ||||||||||
| Synthesis Reference | Not Available | |||||||||
| MSDS | Not Available | |||||||||
| General References | Not Available | |||||||||
